AUSTIN, Texas--(BUSINESS WIRE)--Jun. 13, 2019--
Savara
Inc. (Nasdaq: SVRA), an orphan lung disease company, today announcedthat the Company's Chief Executive Officer, Rob Neville, and Chief
Operating Officer, Taneli Jouhikainen, will present at the JMP
Securities Life Sciences Conference on Wednesday, June 19, 2019 at 11:30
a.m. Eastern Time / 8:30 a.m. Pacific Time in the Fontainebleau room,
The St. Regis, New York.
Interested parties can access a live audio webcast on the Investors page
of the Savara website at www.savarapharma.com/investors/events-presentations/.
Please connect to the Company's website at least 15 minutes prior to the
start of the presentation to ensure sufficient time for any software
download that may be required for the webcast. An archived presentation
will be available on Savara's website for 30 days.
About Savara
Savara is an orphan lung disease company. Savara’s pipeline comprises
Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor
(GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar
proteinosis (aPAP), in Phase 2a development for nontuberculous
mycobacterial (NTM) lung infection in both non-cystic fibrosis (CF) and
CF-affected individuals with chronic NTM lung infection; and AeroVanc, a
Phase 3-stage inhaled vancomycin for treatment of persistent
methicillin-resistant Staphylococcus aureus (MRSA) lung infection
in CF. Savara’s strategy involves expanding its pipeline of potentially
best-in-class products through indication expansion, strategic
development partnerships and product acquisitions, with the goal of
becoming a leading company in its field. The most recent acquisition is
aerosolized amikacin/fosfomycin, a Phase 2-ready combination antibiotic
for which the initial indication will focus on non-CF bronchiectasis
patients with chronic lung infection and frequent exacerbations.
Savara’s management team has significant experience in orphan drug
development and pulmonary medicine, identifying unmet needs, developing
and acquiring new product candidates, and effectively advancing them to
approvals and commercialization. More information can be found at www.savarapharma.com.
(Twitter: @SavaraPharma,
LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/)
View source version on businesswire.com: https://www.businesswire.com/news/home/20190613005663/en/
Source: Savara Inc.
Savara Inc. IR & PR
Anne Erickson (anne.erickson@savarapharma.com)
(512)
851-1366
For IR: Solebury Trout
Gitanjali Jain Ogawa (Gogawa@troutgroup.com)
(646)
378-2949